Werewolf Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	258	140	63	328	-	-
Market Cap Growth	-	121.66%	-80.81%	-	-	-
Enterprise Value	175	57	-52	185	-90	-15
PE Ratio	-3.74	-3.74	-1.17	-1.63	-	-
PS Ratio	12.90	7.01	3.84	-	-	-
PB Ratio	2.31	1.25	0.52	2.15	-	-
P/FCF Ratio	-4.19	-4.19	-1.43	-7.57	-	-
P/OCF Ratio	-4.28	-4.28	-1.55	-7.66	-	-
EV/Sales Ratio	8.77	2.87	-3.15	-	-	-
EV/EBITDA Ratio	-1.85	-1.85	1.01	-3.76	6.33	1.59
EV/EBIT Ratio	-1.67	-1.67	0.96	-3.71	6.00	1.52
EV/FCF Ratio	-1.72	-1.72	1.17	-4.27	4.70	1.53
Debt / Equity Ratio	0.47	0.47	0.12	0.10	-0.05	-0.13
Debt / EBITDA Ratio	-1.68	-1.68	-0.29	-0.32	-0.18	-0.33
Debt / FCF Ratio	-1.56	-1.56	-0.33	-0.36	-0.13	-0.32
Quick Ratio	7.00	7.00	5.68	13.37	17.56	8.86
Current Ratio	7.14	7.14	5.84	13.57	17.58	8.84
Asset Turnover	0.11	0.11	0.10	0	0	-
Interest Coverage	-10.90	-10.90	-	-	-	-26.55
Return on Equity (ROE)	-32.20%	-32.20%	-41.20%	-230.80%	74.10%	-
Return on Assets (ROA)	-20.40%	-20.40%	-32.00%	-126.70%	-47.80%	-
Return on Capital (ROIC)	-24.80%	-24.80%	-40.91%	-29.73%	45.42%	46.94%
Earnings Yield	-14.52%	-26.75%	-85.38%	-61.47%	-	-
FCF Yield	-12.97%	-23.89%	-70.14%	-13.20%	-	-
Buyback Yield / Dilution	-23.50%	-23.50%	-56.40%	-1736.32%	-57.06%	-
Total Shareholder Return	-23.50%	-23.50%	-56.40%	-1736.32%	-57.06%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).